Abarceo Pharma
  • About
  • Team
    • Management
    • Board
    • Scientific Advisors
  • Pipeline
  • News
  • Contact
Select Page
Abarceo attended Biostock’s event in Stockholm

Abarceo attended Biostock’s event in Stockholm

by SD-AbarceoPharma | Sep 26, 2025 | Uncategorized

On September 23, BioStock’s event Investing in Life Science 2025 took place in Stockholm. It was a day full of insights, inspiration, innovation and panel discussions. Abarceo’s CEO Adam Bruce attended the event and presented Abarceo’s development...
Novel approach to treating type 2 diabetes

Novel approach to treating type 2 diabetes

by SD-AbarceoPharma | May 23, 2025 | Diabetes, News & Press releases, VDAC1

We are proud to present groundbreaking data at the 5th Swedish Diabetes Summit, revealing a novel approach to treating type 2 diabetes through VDAC1 oligomerization inhibitors. We share our exciting poster presented by our Principal Scientist Ruchi Jain and our...

Can we reverse diabetes? – Abarceo Pharma aims to develop the solution of the future

by SD-AbarceoPharma | Nov 15, 2024 | Diabetes

World Diabetes Day on November 14 raised awareness of diabetes as one of the greatest public health challenges of our time, along with the importance of ensuring access to adequate care for everyone affected. Claes Wollheim, founder of Abarceo Pharma, has dedicated...

Investing in Life Science 2024 – Presentation

by SD-AbarceoPharma | Nov 14, 2024 | Events, Investors, News & Press releases

Adam Bruce, CEO & Chair of Abarceo Pharma, presents at Investing in Life Science – From Seed To Success. About the event On September 12, 2024, BioStock and Vator Securities hosted the investment-focused event, Investing in Life Science: From Seed to...

Investing in Life Science 2024 – Interview

by SD-AbarceoPharma | Nov 14, 2024 | Events, Investors, News & Press releases

BioStock’s Natasha Bank interviews Adam Bruce, CEO & Chair of Abarceo Pharma, at Investing in Life Science – From Seed To Success.    About the event On September 12, 2024, BioStock and Vator Securities hosted the investment-focused event, Investing in Life...
« Older Entries

Recent Posts

  • Abarceo attended Biostock’s event in Stockholm
  • Novel approach to treating type 2 diabetes
  • Can we reverse diabetes? – Abarceo Pharma aims to develop the solution of the future
  • Investing in Life Science 2024 – Presentation
  • Investing in Life Science 2024 – Interview

Recent Comments

    Abarceo Pharma AB

    Medeon Science Park
    Per Albin Hanssons vä 41, 205 12
    Malmö, Sweden

    Email: info@abarceo.com

    Abarceo Pharma is a Lund University Holding company and was founded in December 2017 by Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi. The company is dedicated to developing novel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.

    ©Copyright 2018 – 2025 | All Rights Reserved | Reg. No. 559139-7160 | Privacy Policy